Association between anti-rituximab antibodies and treatment efficacy of rituximab in membranous nephropathy

Key Points

• To investigate how anti-rituximab antibodies affect the efficacy of rituximab treatment in patients with membranous nephropathy.
• Evaluated relapse rates in adult patients with MN who are ARA positive after rituximab treatment
• Assessed clinical outcomes in RTX-resistant patients treated with obinutuzumab
• ARA positive patients showed a higher relapse rate post-rituximab treatment
• RTX-resistant and ARA positive patients achieved rapid clinical remission with obinutuzumab